advanced search

Welcome: Guest

log in

The Dun & Bradstreet Corporation - Financial and Strategic Analysis Review

Publication Date June 2009
Publisher Global Markets Direct
Product Type Report
Pages 18
ISBN Number not applicable
Product Code GMD09654
Buy this product or for assistance call +44 20 7060 7474

Summary

The Dun & Bradstreet Corporation - Financial and Strategic Analysis Review

The Dun & Bradstreet Corporation (D&B) is a major provider of business information and strategic insights of global enterprises and industries. The company owns and maintains a global database of over 140 million records of businesses. Diverse information solutions of D&B include D&B Risk Management Solutions, D&B Sales & Marketing Solutions, and D&B Internet Solutions. The company ensures quality content in its databases through DUNSRight Quality Process. D&B has its operations across the US, Canada, and in strategic locations across the Europe, Asia-Pacific, and Latin America. The Dun & Bradstreet Corporation is headquartered at Short Hills, New Jersey, the US

Global Markets Direct's The Dun & Bradstreet Corporation - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of The Dun & Bradstreet Corporation. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.

Scope

  • Provides key company information for business intelligence needs.
  • The company's strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
  • The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
  • The report contains critical company information - business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
  • The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
  • Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Reasons to buy

  • A quick "one-stop-shop" to understand the company.
  • Enhance business/sales activities by understanding customers' businesses better.
  • Get detailed information and financial and strategic analysis on companies operating in your industry.
  • Identify prospective partners and suppliers - with key data on their businesses and locations.
  • Capitalize on competitor's weaknesses and target the market opportunities available to them.
  • Compare your company's financial trends with those of your peers / competitors.
  • Scout for potential acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Content

  • List of Tables
  • List of Figures
    • The Dun & Bradstreet Corporation - Key Facts
    • The Dun & Bradstreet Corporation - Business Description
    • The Dun & Bradstreet Corporation - Major Products and Services
    • The Dun & Bradstreet Corporation - History
    • The Dun & Bradstreet Corporation - SWOT Analysis
    • SWOT Analysis - Overview
    • The Dun & Bradstreet Corporation - Strengths
    • Strength - Market Leadership
    • Strength - Consistent Revenue Growth
    • Strength - Focus on Customer Solutions and Services
    • Strength - Strong Growth Prospects
    • Strength - Expanding Operating Margin
    • The Dun & Bradstreet Corporation - Weaknesses
    • Weakness - Pending Cases
    • Weakness - Over-reliance on the US Market
    • Weakness - Limited Liquidity Position
    • The Dun & Bradstreet Corporation - Opportunities
    • Opportunity - Increasing Demand for Customized Solutions
    • Opportunity - New Mobile-Centric Product Line
    • Opportunity - New Launches
    • The Dun & Bradstreet Corporation - Threats
    • Threat - Intellectual Property Risks
    • Threat - Competitive Pressures
    • Threat - Recession in US and Eurozone
    • The Dun & Bradstreet Corporation - Key Competitors
    • The Dun & Bradstreet Corporation - Key Employees
    • The Dun & Bradstreet Corporation - Key Employee Biographies
    • The Dun & Bradstreet Corporation - Company Statement
    • The Dun & Bradstreet Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • The Dun & Bradstreet Corporation - Financial Ratios
    • Financial Ratios - Capital Market Ratios
    • Financial Ratios - Annual Ratios
    • Financial Ratios - Interim Ratios
    • Financial Ratios - Ratio Charts
  • Appendix
    • Methodology
    • Ratio Definitions
    • About Global Markets Direct
    • Contact Us
    • Disclaimer
  • List of Tables
    • The Dun & Bradstreet Corporation, Key Facts
    • The Dun & Bradstreet Corporation, Major Products and Services
    • The Dun & Bradstreet Corporation, History
    • The Dun & Bradstreet Corporation, Key Employees
    • The Dun & Bradstreet Corporation, Key Employee Biographies
    • The Dun & Bradstreet Corporation, Subsidiaries
    • The Dun & Bradstreet Corporation, Ratios based on current share price
    • The Dun & Bradstreet Corporation, Annual Ratios
    • The Dun & Bradstreet Corporation, Interim Ratios
    • Currency Codes
    • Capital Market Ratios
    • Equity Ratios
    • Profitability Ratios
    • Cost Ratios
    • Liquidity Ratios
    • Leverage Ratios
    • Efficiency Ratios
  • List of Figures
    • The Dun & Bradstreet Corporation, Ratio Charts
Delivery Details

PDF:Delivered by email usually within 12 to 24 UK business hours.

Product features / use
Scope Expert Insight/Opinion yes
Profiles In-depth Company Insight yes
Features Contains SWOT Analysis yes

Industry Events

Oncology Market & Patient Access

14 Dec 09 to 16 Dec 09
Prague, Czech Republic
view summary >>

Orphan & Ultra Orphan Drugs

13 Jan 10 to 14 Jan 10
Brussels, Belgium
view summary >>